Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry

被引:2
|
作者
Riveira-Martin, Mercedes [1 ,2 ]
Struelens, Lara [3 ]
Iglesias, Jose Munoz [4 ]
Schoonjans, Werner [3 ]
Tabuenca, Olga [4 ]
Nogueiras, Jose Manuel [5 ]
Gomez, Francisco Javier Salvador [6 ]
Medina, Antonio Lopez [6 ,7 ]
机构
[1] Galicia Hlth Res Inst IISGS, Genet Oncol Radiobiol & Radiointeract Res Grp, Vigo, Spain
[2] Univ Complutense Madrid, Med Sch, Dept Radiol Rehabil & Physiotherapy, Madrid, Spain
[3] Belgian Nucl Res Ctr SCK CEN, Mol, Belgium
[4] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept SERGAS, Vigo, Spain
[5] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept GALARIA, Vigo, Spain
[6] Univ Hosp Vigo, Meixoeiro Hosp, Med Phys & RP Dept GALARIA, Vigo, Spain
[7] Univ Vigo, Dept Funct Biol & Hlth Sci, Vigo, Spain
关键词
Lu-177]Lu-DOTA-TATE; Occupational exposure; Nuclear medicine; Equivalent dose; RECEPTOR RADIONUCLIDE THERAPY; NEUROENDOCRINE TUMORS; LU-177; SAFETY; LU-177-DOTATATE; LU-177-OCTREOTATE;
D O I
10.1186/s40658-023-00592-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: The use of lutetium-177 (Lu-177)-based radiopharmaceuticals in peptide receptor nuclear therapy is increasing, but so is the number of nuclear medicine workers exposed to higher levels of radiation. In recent years, [Lu-177]Lu-DOTA-TATE has begun to be widely used for the treatment of neuroendocrine tumours. However, there are few studies evaluating the occupational radiation exposure during its administration, and there are still some challenges that can result in higher doses to the staff, such as a lack of trained personnel or fully standardised procedures. In response, this study aims to provide a comprehensive analysis of occupational doses to the staff involved in the administration of [Lu-177]Lu-DOTA-TATE.Results: A total of 32 administrations of [Lu-177]Lu-DOTA-TATE (7.4 GBq/session) carried out by a physician and a nurse, were studied. In total, two physicians and four nurses were independently monitored with cumulative (passive) and/or real-time (active) dosemeters. Extremity, eye lens and whole-body doses were evaluated in terms of the dosimetric quantities Hp(0.07), Hp(3) and Hp(10), respectively. It was obtained that lead aprons reduced dose rates and whole-body doses by 71% and 69% for the physicians, respectively, and by 56% and 68% for the nurses. On average, normalised Hp(10) values of 0.65 +/- 0.18 mu Sv/GBq were obtained with active dosimetry, which is generally consistent with passive dosemeters. For physicians, the median of the maximum normalised Hp(0.07) values was 41.5 mu Sv/GBq on the non-dominant hand and 45.2 mu Sv/GBq on the dominant hand. For nurses 15.4 mu Sv/GBq on the non-dominant and 13.9 mu Sv/GBq on the dominant hand. The ratio or correction factor between the maximum dose measured on the hand and the dose measured on the base of the middle/ring finger of the non-dominant hand resulted in a factor of 5/6 for the physicians and 3/4 for the nurses. Finally, maximum normalised Hp(3) doses resulted in 2.02 mu Sv/GBq for physicians and 1.76 mu Sv/GBq for nurses.Conclusions: If appropriate safety measures are taken, the administration of [Lu-177]Lu-DOTA-TATE is a safe procedure for workers. However, regular monitoring is recommended to ensure that the annual dose limits are not exceeded.
引用
收藏
页数:25
相关论文
共 50 条
  • [41] Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE
    Bruvoll, Ragnar
    Blakkisrud, Johan
    Mikalsen, Lars Tore
    Connelly, James
    Stokke, Caroline
    CANCERS, 2023, 15 (04)
  • [42] Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
    Johannes Zellmer
    Hsi-Yu Yen
    Lena Kaiser
    Erik Mille
    Franz Josef Gildehaus
    Guido Böning
    Katja Steiger
    Marcus Hacker
    Peter Bartenstein
    Andrei Todica
    Alexander R. Haug
    Harun Ilhan
    EJNMMI Research, 10
  • [43] Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats
    Zellmer, Johannes
    Yen, Hsi-Yu
    Kaiser, Lena
    Mille, Erik
    Gildehaus, Franz Josef
    Boening, Guido
    Steiger, Katja
    Hacker, Marcus
    Bartenstein, Peter
    Todica, Andrei
    Haug, Alexander R.
    Ilhan, Harun
    EJNMMI RESEARCH, 2020, 10 (01)
  • [44] Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
    del Olmo-Garcia, Maria I.
    Prado-Wohlwend, Stefan
    Bello, Pilar
    Segura, Angel
    Merino-Torres, Juan F.
    CANCERS, 2022, 14 (03)
  • [45] In house labeling and characterization of 177Lu DOTA-TATE
    Yadav, Alok Kumar
    Meera, V
    Banerjee, Sharmila
    Malhotra, A.
    Bal, Chandarsekhar
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [46] Real- world efficacy and safety of re-treatment with [177Lu] Lu-DOTA-TATE in patients with neuroendocrine tumors (NETs)
    Martinez Lago, N. P.
    Hernando Cubero, J.
    Calatayud, A.
    Velazquez, F.
    Anido, U.
    Garcia-Alvarez, A.
    de Matias Leralta, J. M.
    Asadurova, S.
    Cabezas Agricola, J. M.
    Garcia Burillo, D.
    Pubul Nunez, V
    Capdevila, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 208 - 208
  • [47] Real-world efficacy and safety of re-treatment with [177Lu]Lu-DOTA-TATE in patients with neuroendocrine tumors (NETs)
    Velazquez, F.
    Garcia-Burillo, A.
    Pubul Nunez, V.
    Asadurova, S.
    Hernando Cubero, J.
    Martinez-Lago, N.
    Calatayud Cubes, A.
    Anido Herranz, U.
    Garcia-Alvarez, A.
    De Matias Leralta, J.
    Echeverri Diaz, J.
    Suils Ramon, J.
    Calvino, N.
    Canela Coll, T.
    Marusso Fizzani, M.
    Hernandez Cristancho, O.
    Gamez Cenzano, C.
    Capdevila, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S664 - S665
  • [48] Description of an imaging protocol in patients with glioblastoma treated with [177Lu]Lu-DOTA-TATE.
    Canete, E. Cordoba
    Vivancos, M. Caballero
    Corredera, N. Gonzalez
    Ibanez, E. Trivino
    Sanchez, R. Sanchez
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S209 - S209
  • [49] Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma
    Minczeles, Noemie S.
    Bos, Eelke M. M.
    de Leeuw, Reinoud C. C.
    Kros, Johan M. M.
    Konijnenberg, Mark W. W.
    Bromberg, Jacoline E. C.
    de Herder, Wouter W. W.
    Dirven, Clemens M. F.
    Hofland, Johannes
    Brabander, Tessa
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (04) : 1195 - 1204
  • [50] Gastrointestinal NET tumors: The importance of Administered Activity and Absorbed Dose in Relation to Tumor Shrinkage During [177Lu]Lu-DOTA-TATE Treatment
    Kistner, A.
    Sadus, T.
    Nilsson, J.
    Altena, R.
    Larsson, M.
    Hindorf, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S670 - S670